The LDN Research Trust is proud to offer presentations introducing virtually all a practitioner would need to know about the effective use of LDN. For more extensive information on the use of LDN, be sure to register for a Full Ticket or Livestream so that you can also access our additional recorded sessions.
This lecture will describe some of the clinical trial evidence supporting well-accepted chemotherapy regimens for advanced cancers in adults, as well as some of the published human research about LDN. The audience will be challenged to decide if the “standard proven” therapies are actually better than LDN, which is still considered “unproven” by mainstream medicine.
Little is known about cancer and degenerative diseases in correlation with multiple infections with viruses and bacteria. There is more known about single infections with Coxiella burnetii or Epstein Barr Virus in Non Hodgkin Lymphoma, but nothing is known about the possibility of combined multiple infections in cancer.
Medical research has recently been bringing into question the safety and effectiveness of many of our most popular pharmaceutical treatments for mental health issues. With its extremely low risk-profile, its ability to treat autoimmune and mental health issues simultaneously with only transient side effects, LDN offers an attractive, inexpensive, non-addictive, alternative.
Dosing of opioid antagonists for traumatic stress syndromes and dissociative symptoms is discussed. Case studies are used to illustrate the need for different dosing and how this relates to minimizing adverse effects and maximizing beneficial effects. A neurobiological rationale for adverse effects on emotional functioning in these cases is provided, as well as specific strategies how to address such issues. Moreover, different dosing strategies and their integration with psychotherapeutic interventions are discussed.
Caring for patients with chronic pain in a free clinic setting presents its own unique set of challenges. Patients often wait until later in the presentation of their illness to seek care. Obstacles to care can include language barriers, literacy and educational issues, and lack of consistency with health care services. Medication options can be limited due to cost and availability, and patient compliance with the available medications is variable. Patients have limited financial resources and struggle with basic needs such as food, clothing, transportation and housing. Many patients have had traumatic life events, and therefore are dealing with emotional and mental health issues as well.
Low dose naltrexone (LDN) has consistently been demonstrated to be helpful in the treatment of chronic pain from a wide variety of causes. Despite the high prevalence of chronic pain in free clinic patients, the use of LDN has not been common due to issues with cost, availability, and lack of familiarity with the treatment. In this presentation we look at a case series of patients receiving care at a free clinic in the Commonwealth of Virginia, who have been prescribed LDN for chronic pain.
How LDN can be used to treat various gynecologic conditions
LDN therapy has become more accepted in medicine. However, many practitioners of LDN therapy operate from the conventional wisdom of LDN for autoimmune disorders using 1.5 mg to 4.5 mg. However, the original article interviewing Dr. Bihari focus on LDN as an agent that can normalize immune system. Recent articles point to the mechanism by which normalizing immune system including modulation of glial cell function via Toll like receptor 4 (TLR4). Understanding the mechanism of TLR4 opens up whole new clinical implications not considered at this time. The clinical use for utilizing ultra low dose naltrexone or microgram dosing of naltrexone will be reviewed. Lastly, combination therapy with other therapeutic modalities including CBD oil and acupuncture will be discussed.
Persistent symptoms associated with Lyme disease is a controversial topic with conflicting data and clinical opinion regarding the etiology of this illness. Underlying this controversy is research showing the persistence of Borrelia despite repeated courses of antibiotics. This data combined with the observation that there is a clear gender disparity in the development of post-treatment lyme syndrome suggests the common denominator is a maladapted immune-mediated inflammatory response.
Validation for this hyperactive immune response can be supported by numerous lab findings including elevations of C4a, CCL19, TGF-b1, IL-4, IL-6 and IL-10 with correspondingly depressed NK Cell function, TNF-alpha and IL-2 levels. Critical to long term recovery in these patients is modulating the immune system to correct the associated inflammatory response. By upregulating endorphins and enkaphalins in the body, Low Dose Naltrexone (LDN), acting as a non-selective opioid receptor antagonist, can inhibit proliferation of B and T lymphocytes and the corresponding immune responses. In this way, LDN can be a valuable therapeutic tool for addressing chronic inflammation secondary to persistent Borreliosis.
To discuss the actions LDN, combined with other therapies, to treat autoimmune movement disorders.
All forms of memory loss are inflammatory. This interactive seminar will focus on selected etiologies of memory loss that are inflammatory and investigate how low-dose naltrexone may be an effective therapy.
It has long been known that fasting can reduce inflammation and autoimmunity, and may extend life, however this strategy isn’t considered widely practical and has safety concerns.
The unique and special applications and dosing of LDN in the pediatric population
Treatment helps mitigate activation protocols that create speech pathways, decreases disruptive behaviors, and improves immune function
Hypothyroidism is well understood in conventional medicine as an elevated TSH along with associated symptoms. Unfortunately, TSH is determine by the levels of T3 in the pituitary as determined by the type 2 deiodinase. In the periphery, type 1 deiodinase is what converts T4 into T3 while type 3 deiodinase converts T4 into reverse T3. Understanding what might cause a decrease in either type 1 or type 2 or an increase in type 3 deiodinase coupled with low dose naltrexone treatment could greatly improve lab and symptom outcomes in patients with hypothyroidism or for those who experience classical hypothyroid symptoms but have a TSH within range on a lab report.
Many illnesses are amenable to LDN treatment. Looking at LDN as an inflammation intervention widens the scope of which patients may benefit.
This talk with focus on two common connective tissue diseases, Sjogren's Syndromeand Systemic Lupus. There will be a review of both diseases in terms of diagnosis and treatment. In addition, informative case reports will be presented where LDN has been beneficial after standard therapy was not useful. In addition, there will be a brief discussion of why LDN may be an effective treatmentfor both controlling inflammation and disease symptoms.
There is much more to compounding pharmacy than mixing ingredients. This presentation will give a glimpse into the world of compounding pharmacy, the regulations and guidelines that we strive to meet, how to choose a compounding pharmacy, and how to writefor a low dose naltrexone compounded prescription. Specifically, different bases and equipment used in the compounding of low dose naltrexone will be discussed and how to choose the right dosage form for your unique patient.
Many general practitioners may feel intimidated to include LDN into their regular patient care.Dr. Mageruswill present 6 cases from her practice where she has successfully used LDN as an adjunctive therapy to treat infertility, lupus, endometriosis, multiple sclerosis and hashimoto's thyroiditis.
Mast cells are present in most tissues throughout the human body, especially connective tissue, skin, intestinal lining cardiovascular system, nervous system, and reproductive organs. They are part of the allergic response designed to protect us from threat and injury.When the body is exposed to a perceived threat, the mast cells secrete chemical mediators, such as histamine,interleukins, prostaglandins, cytokines, chemokine and various other chemicalsstored in the cytoplasm of the cell. These chemicalmessengers produce both local and systemic effects, such as increased permeability of blood vessels (inflammation and swelling), contraction of smooth muscle (stomach cramps and heart palpitations), and increase mucous production (congestion, sneezing, etc). Historically, we thought of mast cells only in relation to an allergic or anaphylactic response. We now know they play a profound role in immune activation, development of autoimmunity and many other disorders, such as POTS (postural orthostatic tachycardia syndrome). Sadly we are seeing a large increase in patients presenting with mast cell disorders and MCAS. I believe it is in part dueto the onslaught of more pervasiveenvironmental toxins, molds and chemicals.
Where to focus your marketing muscle that will skyrocket your inquiries...even though it seems counter-intuitive
To show the audience how the use of LDN has been used to manage neuropathic pedal disorders.
Discussing the rules, regulations, uses, restrictions, pros/cons of consulting with a health care provider by electronic means (phone, video, web chat, etc...)
Hashimoto's thyroiditis (autoimmune thyroiditis) is the most common cause of hypothyroidism in the United States. It is characterized clinically by a gradual decline in thyroid function due to the immune-mediated destruction of the gland tissue. Hashimoto’s thyroiditis is an inflammatory process, and since low dose naltrexone (LDN) appears to act as an immunomodulator it is can be an excellent adjunct therapy in clinical practice. Additionally, LDN use in patients with Hashimoto’s not only helps reduce a myriad of thyroid-associated symptoms, but can also lead to a reduced thyroid replacement dosing. Many people with Hashimoto’s often exhibit numerous sensitivities and aggravations to different therapies.
Naltrexone is used for many areas of the body. But what about the eyes? This presentation will shed light on the use of Naltrexone for ocular issues from a pharmacist’s perspective, as well as considerations for ocular naltrexone formulations.
Mast cell activation syndrome (MCAS) is a common, yet rarely recognized, chronic multi-system disease with abnormal mast cell (MC) function producing predominantly inflammatory and allergic illness. Gastrointestinal manifestations of MCAS are common. Untreated MCAS can be the explanation for refractory and vexing disorders. The symptoms of MCAS are numerous and affect multiple organs and systems, which further complicates the clinical presentation. MCAS has been estimated to have prevalence of 1%-17% yet is often not considered in differential diagnoses. MCAS is associated with a number of other idiopathic disorders, including hypermobile Ehlers-Danlos syndrome (hEDS) and dysautonomia such as postural orthostatic tachycardia syndrome (POTS). Pain in the muscles, joints, bladder and GI tract are common symptoms in MCAS. These symptoms along with fatigue are potential areas where LDN can help patients.
The old paradigm that immune balance is obtained by regulating T helper1 (Th1)and T helper 2 (Th2) cells has been challenged along with the idea that elevated Th1 is always associated with autoimmune disease. With the differentiation of T helper 17 (Th17) cells from Th1 cells came the realization that the immune system is much more complex than the Th1/Th2 paradigm. Decreasing autoimmunity and chronic infections involves balancing Th17 and Treg cells in addition to Th1 and Th2 cells. Understanding the imbalanced immune cycle that is common in many of our chronic disease patients leads to new treatment modalities including transfer factors, natural anti-inflammatories, and LDN.
This session will review the interactions and assessments in a community pharmacy practice that result in recommendations for LDN therapy initiation. The session will also review complementary therapies for patients seeking functional improvement of immune dysregulation
SIBO, small intestine bacterial overgrowth, is estimated to account for up to 60% of all IBS patients. That’s millions of patients. The core etiology of developing SIBO is due to auto-immune damage to the nerves that stimulate the muscles of the small gut to move contents forward. As a result, the colon backwashes bacteria/archae into the small gut and they proliferate, causing significant symptoms and damage to the small gut lining. Low Dose Naltrexone can be an invaluable tool in working with SIBO patients. It can help reduce the auto-immunity and acts as a gentle prokinetic, helping to move contents forward to prevent SIBO recurrence. Learn about SIBO, auto-immunity, prokinetics at this interesting lecture by a SIBO expert."